JP2024527235A5 - - Google Patents

Info

Publication number
JP2024527235A5
JP2024527235A5 JP2023574356A JP2023574356A JP2024527235A5 JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5 JP 2023574356 A JP2023574356 A JP 2023574356A JP 2023574356 A JP2023574356 A JP 2023574356A JP 2024527235 A5 JP2024527235 A5 JP 2024527235A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034373 external-priority patent/WO2022271722A1/en
Publication of JP2024527235A publication Critical patent/JP2024527235A/ja
Publication of JP2024527235A5 publication Critical patent/JP2024527235A5/ja
Pending legal-status Critical Current

Links

JP2023574356A 2021-06-22 2022-06-21 抗EGFRvIII抗体薬物コンジュゲート及びその使用 Pending JP2024527235A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163213478P 2021-06-22 2021-06-22
US63/213,478 2021-06-22
US202163242929P 2021-09-10 2021-09-10
US63/242,929 2021-09-10
PCT/US2022/034373 WO2022271722A1 (en) 2021-06-22 2022-06-21 Anti-egfrviii antibody drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527235A JP2024527235A (ja) 2024-07-24
JP2024527235A5 true JP2024527235A5 (cg-RX-API-DMAC10.html) 2025-06-25

Family

ID=82655068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574356A Pending JP2024527235A (ja) 2021-06-22 2022-06-21 抗EGFRvIII抗体薬物コンジュゲート及びその使用

Country Status (9)

Country Link
US (1) US20240293566A1 (cg-RX-API-DMAC10.html)
EP (1) EP4359440A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024527235A (cg-RX-API-DMAC10.html)
KR (1) KR20240024061A (cg-RX-API-DMAC10.html)
AU (1) AU2022298653A1 (cg-RX-API-DMAC10.html)
CA (1) CA3212850A1 (cg-RX-API-DMAC10.html)
IL (1) IL309048A (cg-RX-API-DMAC10.html)
MX (1) MX2023014683A (cg-RX-API-DMAC10.html)
WO (1) WO2022271722A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技(上海)有限公司 一种抗体偶联药物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
DK2808393T3 (en) 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP3964237B1 (en) * 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
AU2015229591B2 (en) * 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
CN116059201A (zh) * 2016-06-08 2023-05-05 艾伯维公司 抗egfr抗体药物偶联物
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物

Similar Documents

Publication Publication Date Title
DK2694111T3 (en) Antibody pharmaceutical conjugates
JP2022510964A5 (cg-RX-API-DMAC10.html)
ES2879799T3 (es) Anticuerpo anti-HER2 y conjugado del mismo
JP2024544520A5 (cg-RX-API-DMAC10.html)
JP2017510559A5 (cg-RX-API-DMAC10.html)
JP2019107018A5 (cg-RX-API-DMAC10.html)
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2023515941A5 (cg-RX-API-DMAC10.html)
RU2013108054A (ru) Антитела против а2 тенасцина с и способы их применения
CN113509558B (zh) 四价抗体药物偶联物及其应用
JP2025513721A5 (cg-RX-API-DMAC10.html)
WO2016116399A1 (en) Anti-fibroblast activation protein (fap) antibodies for treatment and diagnosis
JP2025511135A5 (cg-RX-API-DMAC10.html)
JP2023502398A5 (cg-RX-API-DMAC10.html)
WO2022228424A1 (zh) 一种抗egfr/vegf双功能融合蛋白及其用途
TW202525343A (zh) 抗dll3抗體、其抗體-藥物偶聯物及其醫藥用途
CN109414509B (zh) 使用双特异性抗体的抗体药物偶联物平台
JP2023546293A5 (cg-RX-API-DMAC10.html)
CN119744272A (zh) 一种抗ror1蛋白的抗体及其缀合物
EP4417622A1 (en) Anti-cd26 antibody and use thereof
RU2023130344A (ru) КОНЪЮГАТЫ АНТИТЕЛА К EGFRvIII И ЛЕКАРСТВЕННОГО СРЕДСТВА И ПУТИ ИХ ПРИМЕНЕНИЯ
WO2023045859A1 (zh) Cd38单克隆抗体及其应用
CN119156399A (zh) 抗人颗粒蛋白前体的全人源单克隆抗体
JP2024540536A5 (cg-RX-API-DMAC10.html)
JP2022537142A5 (cg-RX-API-DMAC10.html)